Cediranib

Cediranib

Product name:Cediranib
CAS: 288383-20-0
Molecular Formula: C25H27FN4O3
Molecular Weight: 450.51
Product description:An oral antineoplastic drugs, developed by American astrazeneca company, brand name recentin, this product is a highly VEGFR tyrosine kinase inhibitor, can inhibit all known VEGFR tyrosine kinase (including, VEGFR - 2, VEGFR VEGFR - 1-3 and PDGFR). West to Nebuchadnezzar can inhibit the angiogenesis induced by VEGF and angiogenesis survival and growth of human xenograft tumor cells. For non-small cell lung cancer (NSCLC) in patients with stage I study found that sildenafil Nebuchadnezzar with PC scheme combined use of anti-tumor effect is remarkable. Ⅱ/Ⅲ study BR24 for west to Nebuchadnezzar 30 mg as first-line treatment in patients with NSCLC scheme was studied, and prove its have antitumor effect, but with a greater incidence of adverse events, including diarrhea, dehydration, the brotherhood of syndrome, high blood pressure, and neutropenia.
 

 

For more information OR other specifications of the products, please contact us.

Send Enquiry Online

This form is unable to receive your inquiry from aol, hotmail, gmail or others but company email address.For more information OR other products. Please contact us by Email, Tel, Fax or Send online enquiry. We will reply you as soon as possible.

1. Email: sales@pharmaceutiucal-materials.com
2. Tel: +86 592 536 5868
3. WhatsApp: +86 189 6516 2351